• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Drug ‐Drug Interaction of Letermovir and Atorvastatin in Healthy Participants
AbstractLetermovir (MK-8228/AIC246) is a cytomegalovirus (CMV) DNA terminase complex inhibitor for CMV prophylaxis in adult patients undergoing hematopoietic stem cell transplant. It is cytochrome P450 (CYP) 3A inhibitor and inhibits organic anion transporting polypeptide 1B1/3 and breast cancer resistance protein transporters. Atorvastatin (ATV), a commonly used treatment for hypercholesterolemia, is a substrate of organic anion transporting polypeptide 1B1, potentially breast cancer resistance protein, and CYP3A. As letermovir may be coadministered with ATV, the effect of multiple-dose letermovir 480  mg once daily on t...
Source: Clinical Pharmacology in Drug Development - February 14, 2022 Category: Drugs & Pharmacology Authors: Jacqueline B. McCrea, Karsten Menzel, Adedayo Adedoyin, Carolyn R. Cho, Sabrina Fox ‐Bosetti, Sreeraj Macha, Tian Zhao, Fang Liu, Deborah Panebianco, S. Aubrey Stoch, Marian Iwamoto Tags: Original Article Source Type: research

Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants
Clin Pharmacol Drug Dev. 2022 Feb 14. doi: 10.1002/cpdd.1071. Online ahead of print.ABSTRACTLetermovir (MK-8228/AIC246) is a cytomegalovirus (CMV) DNA terminase complex inhibitor for CMV prophylaxis in adult patients undergoing hematopoietic stem cell transplant. It is cytochrome P450 (CYP) 3A inhibitor and inhibits organic anion transporting polypeptide 1B1/3 and breast cancer resistance protein transporters. Atorvastatin (ATV), a commonly used treatment for hypercholesterolemia, is a substrate of organic anion transporting polypeptide 1B1, potentially breast cancer resistance protein, and CYP3A. As letermovir may be coad...
Source: Clinical Genitourinary Cancer - February 14, 2022 Category: Cancer & Oncology Authors: Jacqueline B McCrea Karsten Menzel Adedayo Adedoyin Carolyn R Cho Sabrina Fox-Bosetti Sreeraj Macha Tian Zhao Fang Liu Deborah Panebianco S Aubrey Stoch Marian Iwamoto Source Type: research

Treatment of dyslipidemia in kidney transplantation.
Authors: Ponticelli C, Arnaboldi L, Moroni G, Corsini A Abstract Introduction: Lipid disorders are frequent after kidney transplantation (KT) and KT recipients are considered at high- or very-high cardiovascular risk. Among many concurring factors, a major role is played by immunosuppressants.Areas covered: General measures to manage lipid disorders first include physical activity and diet counseling. Modulating the doses of immunosuppressants also improves dyslipidemia. When lipid-lowering drugs are necessary to control elevated plasma cholesterol and/or triglycerides, statins are the cornerstone for managing hype...
Source: Expert Opinion on Drug Safety - February 21, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Acute onset significant muscle weakness in a patient awaiting liver transplantation: look for statins
We describe a case of Child's C cirrhosis had acute onset significant muscle weakness and improved on statin discontinuation.
Source: Journal of Clinical and Experimental Hepatology - September 15, 2016 Category: Gastroenterology Source Type: research

Effect of the route of stem cell transplantation on its therapeutic potential on induced myopathy in rats: a histological and immunohistochemical study
Conclusion: Mesenchymal stem cells administered either intramuscularly or intravenously have therapeutic potentials for statin-induced myopathy. However, intramuscular route is more effective.
Source: Egyptian Journal of Histology - March 1, 2016 Category: Cytology Tags: Original articles Source Type: research

Colchicine toxicity in renal patients - Are we paying attention?
We report two cases of colchicine toxicity marked by severe neuromyopathy in a diabetic with stage 4 chronic kidney disease (CKD) and a renal transplant recipient. Both patients presented with diarrhea, acute on chronic kidney injury and progressive muscle weakness while on colchicine for several weeks or longer. In addition to kidney disease, risk factors for colchicine toxicity included maintenance therapy with simvastatin in the first patient and cyclosporine in the second. Creatine phosphokinase (CPK) was elevated in both cases at presentation and neurophysiologic studies showed a pattern of severe myopathy with axonal...
Source: Clinical Nephrology - August 7, 2015 Category: Urology & Nephrology Authors: Medani S, Wall C Tags: Clin Nephrol Source Type: research

Statins side effects are minimal, study argues
ConclusionThis meta-analysis pooled results from 29 studies and has shown a very small increased risk of newly diagnosed diabetes mellitus. This is the same as the decreased risk of any cause of death in people taking statins, compared to placebo, to prevent a heart attack or stroke.The researchers point out some limitations to the meta-analysis: Each study did not report on all of the side effects, meaning that for each category of side effect, the number of participants differed. The side effect categories were only included if at least 500 people had reported suffering from it. This means there may be numerous other si...
Source: NHS News Feed - March 13, 2014 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Cardio Notes: Curbing Heart Worries After Liver Transplant
(MedPage Today) -- More intense exercise after a liver transplant may stave off metabolic syndrome, at least in some patients. Also, a possible genetic basis for statin-related myopathy and news about a peripheral stent and a heart valve.
Source: MedPage Today State Required CME - August 12, 2013 Category: Consumer Health News Source Type: news